Where does Dana-farber Cancer Institute, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Dana-farber Cancer Institute, Inc. ranks #616 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Dana-farber Cancer Institute, Inc. hold?

Dana-farber Cancer Institute, Inc. holds 716 US utility patents granted between 2015 and 2025, spanning 49 technology areas.

What is Dana-farber Cancer Institute, Inc.'s Innovation Score?

Dana-farber Cancer Institute, Inc. has an Innovation Score of 64.5 out of 100 (top 2% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Dana-farber Cancer Institute, Inc.'s patent grant rate increasing or decreasing?

Dana-farber Cancer Institute, Inc.'s recent grant velocity is +44% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Dana-farber Cancer Institute, Inc.'s patents?

Dana-farber Cancer Institute, Inc.'s patents average 19.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Dana-farber Cancer Institute, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Dana-farber Cancer Institute, Inc.

Q: What technology areas does Dana-farber Cancer Institute, Inc. focus on?

Dana-farber Cancer Institute, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 493 patents. Grants appear in 49 CPC subclasses total.

USPTO PatentsView assignee record - 716 granted patents across 49 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Dana-farber ranks #616 of 49,997 tracked US assignees by granted-patent volume, with 716 patents across 49 technology areas.

#616
of 49,997 US assignees by volume: Top 2%
by Innovation Score (64.5/100): 19.2
avg claims per patent: +44%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R616 · US Corporation #616 · 716 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MID 716 grants
TOP-DECILE #616/49,997
PHOTO-FINISH Roku
CPC-WIDE A61P · 49 areas
INNOV-STRONG 64.5/100
CLAIMS-RICH 19.2 claims/avg
TYPE-USCORP US Corporation
VEL-UP +44% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Roku, Inc. (±1 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Shenzhen China Star… · near

65
Avent · near

65
Dana-farber Cancer… · this assignee

65
Navico · near

65
Shpp Global B V · near

65
3D Lighting… · lowest

7

What this shows Dana-farber's Innovation Score is 64.5/100 (top 2% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Dana-farber's grants concentrate

Dana-farber Cancer Institute, Inc. is a focused PatentsView assignee: 49 CPC subclasses with 68.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (97 grants) versus a trough of 35 in 2015. By volume, Dana-farber sits between Sanofi and Joled Inc..

Dana-farber's three-year grant acceleration

From 2019–2021 to 2022–2024, Dana-farber Cancer Institute, Inc. moved from 253 to 209 grants (0.83x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,740. See the growth leaderboard.

Sanofi

721
Council OF Scient…

720
Hoya

718
Roku

717
Dana-farber Cance… ◀

716
T-mobile Innovati…

715
FG Innovation

714
Masimo

714
Joled

713

What this shows Dana-farber holds 716 patents at rank #616, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Dana-farber

By rank, the assignees closest to #616 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Dana-farber's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Dana-farber, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (65 here).

Avent, Inc. 65 Shenzhen China Star Optoelectronics Semiconductor Display Technology Co., Ltd. 65 Shpp Global Technologies B.V. 65 Navico, Inc. 65

Similar claim depth

Nearest assignees by average claims per patent (19.2 here).

Novellus Systems, Inc. 19.2 avg CommScope Connectivity UK Limited 19.2 avg Becton Dickinson Rowa Germany GmbH 19.2 avg SR Technologies, Inc. 19.2 avg

Dana-farber's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

65 Top 2% higher than 98% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Dana-farber Cancer Institute, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	35	4.9%
2016	39	5.4%
2017	60	8.4%
2018	62	8.7%
2019	74	10.3%
2020	97	13.5%
2021	82	11.5%
2022	76	10.6%
2023	62	8.7%
2024	71	9.9%
2025partial year	58	8.1%

Which technologies does Dana-farber Cancer Institute, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 493

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 488

C07K - Peptides 244

C07D - Heterocyclic Compounds 235

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 212

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 178

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 163

Y02A - Technologies FOR Adaptation TO Climate Change 67

C12Y - Enzymes 45

C07C - Acyclic OR Carbocyclic Compounds 25

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 20

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 20

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 12

C07J - Steroids 11

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 10

Top 15 of 49 technology areas

Where it ranks

Overall rank by patents

#616

of 49,997 tracked assignees

Innovation Score

64.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Dana-farber Cancer Institute, Inc.'s patent record in context - here's where to go next.

Dana-farber Cancer Institute, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 68.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #616 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Dana-farber Cancer Institute, Inc. against Sanofi, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 64.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.